Sung, H. et al. World Most cancers Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 International locations. CA. Most cancers J. Clin. 71, 209–249 (2021).
Robins, D. J. et al. Mp86-17 the 2017 American joint committee on most cancers eighth version most cancers staging handbook: modifications in staging tips for cancers of the kidney, renal pelvis and ureter, bladder, and urethra. J. Urol. 197, e1163 (2017).
Troisi, J. et al. A serum metabolomic signature for the detection and grading of bladder most cancers. Appl. Sci. 11, 2835 (2021).
Lee, H. H. & Ham, W. S. Perioperative immunotherapy in muscle-invasive bladder most cancers. Transl. Most cancers Res. 9, 6546–6553 (2020).
Yang, Q. et al. Metabolomics biotechnology, purposes, and future traits: a scientific evaluate. RSC Adv. 9, 37245–37257 (2019).
Raja, G., Jung, Y., Jung, S. H. & Kim, T. J. 1H-NMR-based metabolomics for most cancers concentrating on and metabolic engineering—a evaluate. Course of Biochem. 99, 112–122 (2020).
Liu, X. et al. LC-MS-based plasma metabolomics and lipidomics analyses for differential analysis of bladder most cancers and renal cell carcinoma. Entrance. Oncol. 10, 717 (2020).
Pan, Z. & Raftery, D. Evaluating and mixing NMR spectroscopy and mass spectrometry in metabolomics. Anal. Bioanal. Chem. 387, 525–527 (2007).
Ng, Ok., Stenzl, A., Sharma, A. & Vasdev, N. Urinary biomarkers in bladder most cancers: A evaluate of the present panorama and future instructions. Urol. Oncol. Semin. Orig. Investig. 39, 41–51 (2021).
Batista, R. et al. Biomarkers for bladder most cancers analysis and surveillance: A complete evaluate. Diagnostics 10, 39 (2020).
Walsh, M. C., Brennan, L., Malthouse, P. G., Roche, H. M. & Gibney, M. J. Impact of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of wholesome people 13. Am. J. Clin. Nutr. 84, 531–539 (2006).
Gupta, A. et al. NMR-derived focused serum metabolic biomarkers appraisal of bladder most cancers: A pre- and post-operative analysis. J. Pharm. Biomed. Anal. 183, 113134 (2020).
Bansal, N. et al. Low- and high-grade bladder most cancers willpower through human serum-based metabolomics strategy. J. Proteome Res. 12, 5839–5850 (2013).
Cao, M., Zhao, L., Chen, H., Xue, W. & Lin, D. NMR-based metabolomic evaluation of human bladder most cancers. Anal. Sci. 28, 451–456 (2012).
Amara, C. S. et al. Serum metabolic profiling recognized a definite metabolic signature in bladder most cancers people who smoke: A key metabolic enzyme related to affected person survival. Most cancers Epidemiol. Biomarkers Prev. 28, 770–781 (2019).
Vantaku, V. et al. Massive-scale profiling of serum metabolites in African American and European American sufferers with bladder most cancers reveals metabolic pathways related to affected person survival. Most cancers 125, 921–932 (2019).
Sahu, D., Lotan, Y., Wittmann, B., Neri, B. & Hansel, D. E. Metabolomics evaluation reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder most cancers. Most cancers Med. 6, 2106–2120 (2017).
Tan, G. et al. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder most cancers. Sci. Rep. 7, 1–11 (2017).
Lin, L. et al. LC-MS based mostly serum metabonomic evaluation for renal cell carcinoma analysis, staging, and biomarker discovery. J. Proteome Res. 10, 1396–1405 (2011).
Zhou, Y. et al. The event of plasma pseudotargeted GC-MS metabolic profiling and its software in bladder most cancers. Anal. Bioanal. Chem. 408, 6741–6749 (2016).
Lepara, Z. et al. Serum malondialdehyde (MDA) stage as a possible biomarker of most cancers development for sufferers with bladder most cancers. Rom. J. Intern. Med. 58, 146–152 (2020).
Lin, L. et al. LC-MS-based serum metabolic profiling for genitourinary most cancers classification and most cancers type-specific biomarker discovery. Proteomics 12, 2238–2246 (2012).
MassBank of North America. Obtainable at: https://mona.fiehnlab.ucdavis.edu/. Accessed: eighth June 2022
Mass Spectrometry Knowledge Middle, NIST. ass Spectral Library Obtainable at: https://chemdata.nist.gov/. Accessed 1st April 2022.
Pang, Z. et al. MetaboAnalyst 50: Narrowing the hole between uncooked spectra and practical insights. Nucleic Acids Res. 49, W388–W396 (2021).
Ho, S. Y., Phua, Ok., Wong, L. & Bin Goh, W. W. Extensions of the exterior validation for checking realized mannequin interpretability and generalizability. Patterns 1, 100129 (2020).
Okuda, S. et al. KEGG Atlas mapping for world evaluation of metabolic pathways. Nucleic Acids Res. 36, W423–W426 (2008).
Han, J., Li, Q., Chen, Y. & Yang, Y. Latest metabolomics evaluation in tumor metabolism reprogramming. Entrance. Mol. Biosci. 8, 763902 (2021).
Besiroglu, H. Lipid metabolism profiling and bladder most cancers. Metabolomics Open Entry 5, 1–4 (2015).
Wolrab, D., Jirásko, R., Chocholoušková, M., Peterka, O. & Holčapek, M. Oncolipidomics: Mass spectrometric quantitation of lipids in most cancers analysis. TrAC Tendencies Anal. Chem. 120, 10 (2019).
Lu, Y. et al. Comparability of hepatic and serum lipid signatures in hepatocellular carcinoma sufferers results in the invention of diagnostic and prognostic biomarkers. Oncotarget 9, 5032 (2018).
Lee, G. B., Lee, J. C. & Moon, H. Plasma lipid profile comparability of 5 totally different cancers by nanoflow ultrahigh efficiency liquid chromatography-tandem mass spectrometry. Anal Chim Acta https://doi.org/10.1016/j.aca.2019.02.021 (2019).
Wang, X. et al. A novel human phosphatidylethanolamine-binding protein resists tumor necrosis issue α-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization*. J. Biol. Chem. 279, 45855–45864 (2004).
Wang, X. et al. Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast most cancers cells to tumor necrosis factor-alpha-induced apoptosis and cell progress arrest. Clin. Most cancers Res. 11, 7545–7553 (2005).
Yao, Y. et al. Exogenous phosphatidylethanolamine induces apoptosis of human hepatoma HepG2 cells through the bcl-2/bax pathway. World J. Gastroenterol. 15, 1751 (2009).
Yagi, T. et al. Challenges and inconsistencies in utilizing lysophosphatidic acid as a biomarker for ovarian most cancers. Cancers 11, 520 (2019).
Ravipati, S., Baldwin, D. R., Barr, H. L., Fogarty, A. W. & Barrett, D. A. Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung most cancers sufferers. Metabolomics 11, 1600–1611 (2015).
Taylor, L. A., Arends, J., Hodina, A. Ok., Unger, C. & Massing, U. Plasma lyso-phosphatidylcholine focus is decreased in most cancers sufferers with weight reduction and activated inflammatory standing. Lipids Well being Dis. 6, 1–8 (2007).
Li, J. et al. Distinct plasma lipids profiles of recurrent ovarian most cancers by liquid chromatography-mass spectrometry. Oncotarget 8, 46834 (2017).
Zhang, F. et al. The predictive and prognostic values of serum amino acid ranges for clear cell renal cell carcinoma. Urol. Oncol. Semin. Orig. Investig. 35, 392–400 (2017).
Tan, B. et al. Metabonomics identifies serum metabolite markers of colorectal most cancers. J. Proteome Res. https://doi.org/10.1021/pr400337b (2013).
Shen, S. et al. A plasma lipidomics technique reveals perturbed lipid metabolic pathways and potential lipid biomarkers of human colorectal most cancers. J. Chromatogr. B 1068–1069, 41–48 (2017).
Zhao, Z. et al. Plasma lysophosphatidylcholine ranges: potential biomarkers for colorectal most cancers. J Clin Oncol 25, 2696–2701 (2007).
Cala, M. P. et al. Multiplatform plasma fingerprinting in most cancers cachexia: a pilot observational and translational research. J. Cachexia. Sarcopenia Muscle 9, 348–357 (2018).
Yao, Z. et al. Serum metabolic profiling and options of papillary thyroid carcinoma and nodular goiter. Mol. Biosyst. 7, 2608–2614 (2011).
Li, Y. et al. Thymol inhibits bladder most cancers cell proliferation through inducing cell cycle arrest and apoptosis. Biochem. Biophys. Res. Commun. 491, 530–536 (2017).
Ye, Z., Liang, Z., Mi, Q. & Guo, Y. Limonene terpenoid obstructs human bladder most cancers cell (T24 cell line) progress by inducing mobile apoptosis, caspase activation, G2/M section cell cycle arrest and stops most cancers metastasis. JBUON 25, 280–285 (2020).
Wang, X., Wang, J., Rao, B. & Deng, L. I. Intestine flora profiling and fecal metabolite composition of colorectal most cancers sufferers and wholesome people. Exp. Ther. Med. 13, 2848–2854 (2017).
Nizioł, J. et al. Metabolomic research of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA. Anal. Bioanal. Chem. 410, 3859–3869 (2018).
Ganti, S. et al. Urinary acylcarnitines are altered in human kidney most cancers. Int. J. Most cancers 130, 2791–2800 (2012).
Wittmann, B. M. et al. Bladder most cancers biomarker discovery utilizing world metabolomic profiling of urine. PLoS ONE 9, e115870 (2014).
Schroeder, M. A. et al. The biking of acetyl-coenzyme A by means of acetylcarnitine buffers cardiac substrate provide: A hyperpolarized 13C magnetic resonance research. Circ. Cardiovasc. Imaging 5, 201–209 (2012).
Jin, X. et al. Prognosis of bladder most cancers and prediction of survival by urinary metabolomics. Oncotarget 5, 1635–1645 (2014).
Rodrigues, D. et al. Biomarkers in bladder most cancers: A metabolomic strategy utilizing in vitro and ex vivo mannequin programs. Int. J. Most cancers 139, 256–268 (2016).